权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA

通过游离 DNA 中的基因沉默景观监测免疫治疗反应

基本信息

批准号：
10760450
负责人：
Michael T Barrett
金额：
$ 39.8万
依托单位：
BINARY GENOMICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10760450
关键词：
Address Benchmarking Biological Assay Biological Markers Biological Specimen Banks Blood Blood Tests Budgets Cancer Patient Characteristics Circulation Clinical Clinical Sensitivity Clinical Trials Complex DNA Probes Data Detection Development Epigenetic Process Gene Silencing Genome Genomic Segment Genomics Goals Hypermethylation Immune Immune checkpoint inhibitor Immunotherapeutic agent Immunotherapy Kinetics Malignant Neoplasms Malignant neoplasm of lung Measurement Measures Methods Methylation Monitor Mutation Non-Small-Cell Lung Carcinoma Outcome Paper Patients Pattern Performance Phase Plasma Prediction of Response to Therapy Publishing Reproducibility Scanning Screening for cancer Sensitivity and Specificity Signal Transduction Small Business Innovation Research Grant Somatic Mutation Specific qualifier value Specificity Surveys Technology Therapeutic Therapeutic Equivalency Treatment Efficacy Tumor Tissue Universities Validation Work cancer genome cancer immunotherapy cancer type cell free DNA checkpoint therapy chemotherapy clinical practice clinical predictors commercialization density disorder control effective therapy exome sequencing immune cell infiltrate improved ineffective therapies liquid biopsy mutant patient subsets promoter radiological imaging responders and non-responders response serial imaging side effect survival outcome tumor tumor DNA validation studies virtual

项目摘要

ABSTRACT: Immunotherapies produce remarkable, long-term responses in subsets of patients with non-small cell lung cancer, but unfortunately, most patients do not respond to such treatment. Current biomarkers to predict which patients will benefit have limited accuracy, and decisions to continue or suspend treatment are mainly guided by monitoring of radiographic changes in tumor size. However, unusual immune-related response patterns such as pseudo-progression, mixed response, and delayed response can make scans difficult to interpret. Circulating tumor DNA (ctDNA) has emerged as a highly promising biomarker for monitoring immunotherapy efficacy. Several studies involving various immunotherapy agents and multiple types of cancer have demonstrated that early reduction in ctDNA levels during treatment are predictive of tumor response and improved survival outcomes. However, existing technologies that measure ctDNA by probing for common somatic mutations will fail patients whose tumors lack these mutations. This limitation is being addressed by creating customized assays based on patient-specific tumor mutation profiles; but this approach is complex, expensive, and slow. We have developed a ctDNA assay technology based on detection of epigenetic features that are found in virtually all cancer cell genomes. Preliminary data indicate that our approach has broad patient coverage and can be applied to multiple types of cancer without requiring tumor profiling and assay customization. As proof of concept, we aim to establish the utility of our assay technology for monitoring of lung cancer immunotherapy response. In this Phase I SBIR application, we will evaluate the analytical and baseline clinical performance characteristics of the assay technology, with a plan for a larger follow-on clinical utility study in Phase II. The analytical validation and baseline clinical performance metrics will be benchmarked against existing commercial mutation-based ctDNA assays to justify further development and commercialization of our technology.

文摘: